본문으로 이동
Ravington
피드로 돌아가기
AI

OpenAI researcher Miles Wang is in talks to start a drug discovery venture with a 2 billion dollar valuation

TechCrunch
WhatsApp

핵심 요약

  • OpenAI researcher Miles Wang plans to establish an AI-driven drug discovery venture.
  • The target valuation of the new venture to be established stands out as 2 billion dollars.
  • It is reported that the venture capital firm Lightspeed is holding talks to lead the investment round.

숫자로 보기

2 billion dollar valuation

OpenAI researcher Miles Wang is reported to be launching a new venture focusing on AI-driven drug discovery. The new company is rumored to have a pre-money valuation of 2 billion dollars.

Sources state that Lightspeed Ventures is in talks with the company to lead this funding round. The development shows that investments in the practical applications of artificial intelligence technologies in the pharmaceutical and healthcare sectors continue to gain momentum.

반응 남기기

이 기사에 대해 질문

답변은 이 기사만을 바탕으로 AI가 생성합니다.

자주 묻는 질문

In which field will the venture Miles Wang plans to establish operate?
The new venture is planned to focus on drug discovery and development processes using artificial intelligence technologies.
What is the target market valuation of the company?
According to the information obtained, the startup's valuation is expected to reach 2 billion dollars following the funding round.
Which organization is being discussed to lead the investment round?
It is stated that the venture capital firm named Lightspeed is in discussions with the company to spearhead this funding round.

AI가 생성한 짧은 요약입니다. 전문은 출처에 있습니다.

출처에서 전문 읽기techcrunch.com

다른 출처의 보도 · 2 · 2 개국

ATnl

관련 뉴스